Ixekizumab is a monoclonal antibody used to treat certain inflammatory conditions. It is commonly prescribed for treatment of moderate to severe psoriatic arthritis. By targeting and inhibiting interleukin-17A (IL-17A), a cytokine involved in inflammatory and immune responses, Ixekizumab helps reduce the symptoms of these conditions.

Ixekizumab is administered via subcutaneous injection. It comes in prefilled syringes or autoinjectors, and the injections are typically given once every two to four weeks, depending on the specific condition and treatment plan prescribed by the doctor.

Ixekizumab is not recommended for individuals with a history of severe allergic reactions to the medication or its components. Additionally, patients with active infections or tuberculosis should not use Ixekizumab. A thorough medical history and evaluation by a doctor is necessary to determine if Ixekizumab is a safe option.

The safety of Ixekizumab during pregnancy and breastfeeding has not been well established. Women who are pregnant, planning to become pregnant, or breastfeeding should discuss the potential risks and benefits with their doctor.

The time it takes for Ixekizumab to show improvement in symptoms can vary among individuals. Some patients may notice a reduction in symptoms within the first few weeks of treatment, while for others, it may take longer. Continuous use as prescribed is important for achieving the best results.

Ixekizumab should be stored in the refrigerator at a temperature between 2°C to 8°C (36°F to 46°F). It should not be frozen. If necessary, Ixekizumab can be kept at room temperature (up to 30°C or 86°F) for up to five days, but it must be used within this timeframe or discarded. The medication should be kept in its original packaging to protect it from light and kept out of reach of children and pets.